Genes-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2020-12-17 1e0cf3e5m18(暂无匿称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好

95 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2022-05-11 ms9000000734077640

投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？

50 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2022-05-23 ms1000001833329884

一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了

72 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2020-08-11 145d9400m83暂无昵称

还收国人的文章吗

136 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2022-04-07 ms8000001846163417

偏重的研究方向：肿瘤;生物信息
经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。

68 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2022-02-18 liuli1991dr

偏重的研究方向：生信;基因
经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒

60 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2020-05-14 ms1913270821714094

审稿速度:2.0
经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。

320 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2021-08-16 莱纳德

偏重的研究方向：生物信息;肿瘤
经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲

60 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2018-06-20 windowsie

审稿速度:2.0
经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018

230 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=908797, encodeId=7fc0908e9716, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，两次修改，最后还是悲剧。刊物长期看好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Thu Dec 17 10:10:39 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218790, encodeId=c0fe1218e9021, content=投稿一周，目前依旧是pending review无动静，问一下有经历过这个阶段的伙伴们都多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49235689529, createdName=ms9000000734077640, createdTime=Wed May 11 16:59:28 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221667, encodeId=4f8e122166e0b, content=一篇质量还行的肿瘤生信3天模板拒，后来投了个分更高的期刊中了。但是genes近期也有极其低级的肿瘤生信文章，怎么过的初审？一看不是大陆，不是医院，懂了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8b5460993, createdName=ms1000001833329884, createdTime=Mon May 23 03:36:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807482, encodeId=82fe80e482ea, content=还收国人的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Tue Aug 11 15:32:35 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209237, encodeId=0957120923e2b, content=偏重的研究方向：肿瘤;生物信息 经验分享：审稿就要收钱吗，不管接不接收吗？我前两天投的，今天来邮件说要交CHF 2160。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e59e5610533, createdName=ms8000001846163417, createdTime=Thu Apr 07 14:59:52 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194781, encodeId=425b1194e8138, content=偏重的研究方向：生信;基因 经验分享：传言MDPI不收中国医院的文章不知是否可靠？投了生信+验证的一篇文章，秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ccf2600009, createdName=liuli1991dr, createdTime=Fri Feb 18 12:09:03 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860548, encodeId=87b7860548f2, content=审稿速度:2.0 经验分享：**杂志，投一篇文章，先是通知接收，proof，交版面费，一切弄好后，发现投稿系统中文章不见了，发邮件问，几天才回复，通知拒稿。拿人当猴耍，极不严谨。大家慎投。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f70b5414147, createdName=ms1913270821714094, createdTime=Thu May 14 14:18:48 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008241, encodeId=0b30100824168, content=偏重的研究方向：生物信息;肿瘤 经验分享：投IJMS三天被拒，过来投这个也是三天被拒，也没有理由🥲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9365264418, createdName=莱纳德, createdTime=Mon Aug 16 09:00:48 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558112, encodeId=187855811202, content=审稿速度:2.0 经验分享：投的GENES的Special Issue，Received: 3 May 2018 / Revised: 28 May 2018 / Accepted: 12 June 2018 / Published: 18 June 2018, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=850c1668377, createdName=windowsie, createdTime=Wed Jun 20 00:33:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911547, encodeId=570891154ed9, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Mon Dec 28 09:51:41 CST 2020, time=2020-12-28, status=1, ipAttribution=)]

2020-12-28 1e0cf3e5m18(暂无匿称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：坚决不收中国医院的文章，对来自非医院的中国文章也不友好，很挑剔，急着毕业慎重投稿，否则耗费时间

90 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务